Navigation Links
ExonHit Therapeutics Reports Advancements in the Clinical Development of EHT 0202, its Phase II Drug for Alzheimer's Disease
Date:2/26/2009

nt's current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those anticipated.

In addition, ExonHit Therapeutics, its shareholders, and its affiliates, directors, officers, advisors and employees have not verified the accuracy of, and make no representations or warranties in relation to, statistical data or predictions contained in this press release that were taken or derived from third party sources or industry publications, and such statistical data and predictions are used in this press release for information purposes only.

Finally, this press release may be drafted in the French and English languages. In an event of differences between the texts, the French language version shall prevail.

References

[1] Marcade M, Bourdin J, Loiseau N, Peillon H, Rayer A, Drouin D, Schweighoffer F, Desire L. Etazolate, a neuroprotective drug linking GABAA receptor pharmacology to amyloid precursor protein processing. Journal of Neurochemistry. 2008; 106: 392-404

[2] Pando M, Marcade M, Peillon H, Rayer A, Drouin D, Desire L. An alpha-secretase stimulator drug for cognitive disorders associated with neurodegeneration. Presented at the 12th congress of the European Federation of Neurological Societies; 23-26 August, 2008; Madrid, Spain

[3] WHO 2001. Azheimer's disease: The Brain Killer.

WHO website: http://www.searo.who.int/en/Section1174/Section1199/Section1567/Section1823_8 066.htm (Due to the length of this URL, it may be necessary to copy and paste this hyperlink into your Internet browser's URL address field. Remove the space if one exists.)


'/>"/>
SOURCE ExonHit Therapeutics SA
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine technology :

1. ExonHit Therapeutics Expands Strategic Collaboration With Allergan
2. ExonHits EHT 0202 Counters Scopolamines Detrimental Effects on Cognition in Humans
3. BN ImmunoTherapeutics Updates on Phase I/II Studies With Breast Cancer Vaccine
4. Cell Therapeutics and IDIS Announce Agreement for a European Named Patient/Compassionate Use Program for Pixantrone
5. Cerenis Therapeutics In-Licenses Intellectual Property for New Treatment of Aortic Valve Stenosis
6. PTC Therapeutics Completes Enrollment of Pivotal Trial in Muscular Dystrophy
7. DNA Therapeutics Closes 2.2 Million EUR Series A Financing Round
8. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
9. Duska Therapeutics Completes Corporate Name Change to Cordex Pharma
10. Phico Therapeutics Receives GBP1 Million Award From the Wellcome Trust to Take Anti-MRSA Nasal Product Through Early Clinical Trials
11. Pixantrone Pre-NDA Communication from FDA Provides Cell Therapeutics Basis to Begin Rolling NDA Submission

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/23/2009)...23/PRNewswire-FirstCall/--WoundManagementTechnolog...viderofspecialtymedicalproducts,announcedthatithas...hensivemanagementbusinessupdatetoillustratethedeve...lesincreased33.5%to$102,926vs.Q32008salesof$77,084...$3,327,892vs.Q32008shareholderequityof$(321,257) ...
(Date:11/23/2009)...wswire-FirstCall/--CordBloodAmerica,Inc.(OTCBullet...ationcompany( http://www.cordblood-america.com )fo...biologicalinsurancepolicy,tofamiliesnationwideandi...interviewwithCEOandco-founderMatthewSchisslerisnow...ip.tv/file/2875811 . ,, Intheinterview,Mr.Schis...
(Date:11/23/2009).../PRNewswire-FirstCall/--RaptorPharmaceuticalCorp.(...edthepresentationofclinicaltrialdataonNGX426,theCo...eceptorantagonist,atthe12thInternationalConference...nNovember20-21inSanFrancisco.Theresultsofthestudyl...logyattheCenterforPainMedicineoftheUniversityofCal...
Breaking Medicine Technology:Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 2Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 3Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 4Wound Management Technologies (OTCBB: WNDM) Reports Revenue Increase of 33.5%; Posts Evidence-Based Studies for CellerateRx; and Business Update 5Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 2Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 3Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 4Raptor Pharmaceutical Corp. Announces Positive Data on NGX426 in the Potential Treatment of Neuropathic Pain 5No major role for fish in the prevention of heart failure 58482 1No major role for fish in the prevention of heart failure 58482 2No major role for fish in the prevention of heart failure 58482 3Combining sun sand and science in the Bahamas 10172 1Combining sun sand and science in the Bahamas 10172 2Combining sun sand and science in the Bahamas 10172 3Spallation Neutron Source first of its kind to reach megawatt power 10168 1Spallation Neutron Source first of its kind to reach megawatt power 10168 2
...to Meet Pace of Innovations and a Health Conscious...SNewswire/ -- The Food,and Drug Administration (FD...he history of healthcare, Commissioner Andrew von,... Institute,s 50th,Annual Conference April 12 in Be...ys to use its limited,financial and personnel reso...
...a 24 April 2007. Giaconda Ltd (ASX: GIA) today,ann...DA) has,approved the Company,s Investigational New...nt of MyocondaR to treat patients with,Crohn,s Dis...erculosis (MAP). , ,The Company understands that i...o be submitted to the FDA for this indication. The...
Other Medicine Technology:FDLI 50th Annual Meeting Heralds New ERA in Healthcare Innovations,FDA Regulations 2FDA approves MyocondaR IND for MAP in Crohn's Disease 2FDA approves MyocondaR IND for MAP in Crohn's Disease 3FDA approves MyocondaR IND for MAP in Crohn's Disease 4
(Date:11/23/2009)....J. The Center for Science Writings at Stevens In...of God," a talk by Robert Wright, journalist and f...009, 4:00-5:30 p.m. at the Babbio Center for Techn...open to the public and the media., In his new bo...ist Robert Wright, renowned for his popular works ...
(Date:11/23/2009)... Minn. -- Major medical errors self-reported by Am...ut and depression. Those findings appear today in ...o Clinic-led study included collaborators from Joh..., In the confidential study, nearly 9 percent ... error in the three months prior to being surveyed...
(Date:11/23/2009)...ON, Va. The Infectious Diseases Society of Americ... administration and the European Union to further ...f 10 new antibiotics within the next 10 years, kno...rganization (WHO) has identified antimicrobial res...man health. , A new European Union report confir...
(Date:11/23/2009)... in home-based settings get far more screen time ... , MONDAY, Nov. 23 (HealthDay News) --Young ...levision every day than previous reports have foun..., a new study finds. , Researchers from Seattle...ton surveyed day-care directors to find out how mu...
(Date:11/23/2009)... iCRco is proud to announce its parti...nd received the highest grade possible amongst all...er to be rated “A” in sales, service a...satisfaction in software functionality. iCRco is v...ade by the most prestigious research firm in medic...
Breaking Medicine News(10 mins):Health News:Burnout and mental distress strongly related to errors by US surgeons 2Health News:10 x '20: ID experts call for 10 new antibiotics by 2020 2Health News:10 x '20: ID experts call for 10 new antibiotics by 2020 3Health News:Day Care Boosts Kids' TV Time 2Health News:Day Care Boosts Kids' TV Time 3Health News:iCRco is the Only CR Vendor to Receive the Highest Grade “A” in All Fields by KLAS 2Health News:iCRco is the Only CR Vendor to Receive the Highest Grade “A” in All Fields by KLAS 3
... Institute of Technology are proposing a revolutio...ngioplasty problem// of restenosis (re-clogging of...gioplasties were performed in the United States in...ted into clogged arteries and inflated to open blo...
...multiple sites of care may now be able to reduce t...n//, according to a study that will appear in the ...e. The trial was led by Eric Coleman, MD, an ...lth Care Policy. The Care Transitions Interv...
...lifornia, San Diego and Yale University have disco...thuringiensis, a bacterium sprayed// on crops by o...effective at treating hookworm infections in labor...he way for the development of more effective treat...
... asthma who were treated with anti-tumor necrosis ...body, experienced significantly// fewer disease ex... This research appears in the first issue for Oct... Ph.D., of the National Heart and Lung Institute a...
...r socks and make healthy lifestyle changes. Enough...ng at epidemic proportions//. Apart from overweigh...is also the cause of many chronic illnesses. The A...ercise and proper diet. The American Cancer ...
...ttending Montessori schools have an advantage over...evelopment. However, an early education researcher...// In this study, thirty 5-year old kids a...attending non-Montessori Milwaukee schools were al...
Other Medicine News:Health News:Novel Technique Would Prevent Re-Clogged Arteries 2Health News:'Health Care Coaches' Can Help Reduce Patient Bills, Rehospitalization 2Health News:Bacterial Protein Shows Promise in Treating Intestinal Parasites 2Health News:Bacterial Protein Shows Promise in Treating Intestinal Parasites 3Health News:Monoclonal Antibody Reduces Exacerbations in Asthmatics 2Health News:Montessori Schools kids do better in Reading and Math 2
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
...ional reference laboratory and a worldwide leader ... ARUP offers an extensive test menu of highly comp...mic pathology. Owned by the University of Utah, AR... the nation's university teaching hospitals and ch...
Medicine Products: